Last reviewed · How we verify
Chronic- PF-06480605 450 mg SC Q4W — Competitive Intelligence Brief
marketed
pharmacological class not specified
IL-4 receptor alpha subunit
Immunology
Live · refreshed every 30 min
Target snapshot
Chronic- PF-06480605 450 mg SC Q4W (chronic-pf-06480605-450-mg-sc-q4w) — Pfizer.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Chronic- PF-06480605 450 mg SC Q4W TARGET | chronic-pf-06480605-450-mg-sc-q4w | Pfizer | marketed | pharmacological class not specified | IL-4 receptor alpha subunit | |
| Rimegepant/BHV3000 | rimegepant-bhv3000 | Pfizer | marketed | pharmacological class not specified | calcitonin gene-related peptide receptor (CGRPR) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (pharmacological class not specified class)
- Pfizer · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Chronic- PF-06480605 450 mg SC Q4W CI watch — RSS
- Chronic- PF-06480605 450 mg SC Q4W CI watch — Atom
- Chronic- PF-06480605 450 mg SC Q4W CI watch — JSON
- Chronic- PF-06480605 450 mg SC Q4W alone — RSS
- Whole pharmacological class not specified class — RSS
Cite this brief
Drug Landscape (2026). Chronic- PF-06480605 450 mg SC Q4W — Competitive Intelligence Brief. https://druglandscape.com/ci/chronic-pf-06480605-450-mg-sc-q4w. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab